{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:43Z","timestamp":1787582383106,"version":"build-2736575974"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiological Methods"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.mimet.2023.106876","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T19:18:29Z","timestamp":1703099909000},"page":"106876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Nanoparticle-based platforms for targeted drug delivery to the pulmonary system as therapeutics to curb cystic fibrosis: A review"],"prefix":"10.1016","volume":"217-218","author":[{"given":"Sujoy","family":"Rano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahana","family":"Bhaduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mimet.2023.106876_bb0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fphar.2018.00228","article-title":"Risk assessment and risk minimization in nanomedicine: a need for predictive, alternative, and 3Rs strategies","volume":"9","author":"Accomasso","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.mimet.2023.106876_bb0010","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/cells9122659","article-title":"Nano-based theranostic tools for the detection and elimination of senescent cells","volume":"9","author":"Adamczyk-Grochala","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0015","doi-asserted-by":"crossref","first-page":"1065986","DOI":"10.3389\/fchem.2023.1065986","article-title":"Green synthesis and characterization of silver nanoparticles through the Piper cubeba ethanolic extract and their enzyme inhibitory activities","volume":"22","author":"Ahmad","year":"2023","journal-title":"Front. Chem."},{"key":"10.1016\/j.mimet.2023.106876_bb0020","article-title":"Developing ciprofloxacin dry powder for inhalation: a story of challenges and rational design in the treatment of cystic fibrosis lung infection","volume":"121388","author":"Alhajj","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0025","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/polym14061221","article-title":"Broad-spectrum theranostics and biomedical application of functionalized nanomaterials","volume":"14","author":"Alshamrani","year":"2022","journal-title":"Polymers"},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"01","key":"10.1016\/j.mimet.2023.106876_bb0035","doi-asserted-by":"crossref","first-page":"040","DOI":"10.1055\/s-0039-1694964","article-title":"A novel pathogenic variant of the CFTR gene in a patient with cystic fibrosis phenotype\u2014c. 4096A> T","volume":"9","author":"Arslan","year":"2020","journal-title":"J. Pediatr. Genet."},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0040","first-page":"18","article-title":"Nanomedicine for respiratory diseases","volume":"11","author":"Bahadori","year":"2012","journal-title":"Tanaffos."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del\u2013Gating and\u2013residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"NEJM."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.mimet.2023.106876_bb0055","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.3390\/ijms231810956","article-title":"The CFTR amplifier nesolicaftor rescues TGF-\u03b21 inhibition of modulator-corrected F508del CFTR function","volume":"23","author":"Bengtson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0060","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cells11060984","article-title":"Novel insights into the therapeutic potential of lung-targeted gene transfer in the most common respiratory diseases","volume":"11","author":"Bisserier","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0065","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mimet.2023.106876_bb0070","first-page":"99","article-title":"Pathogenesis of cystic fibrosis airways disease","volume":"112","author":"Boucher","year":"2001","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2165\/00003495-198631020-00002","article-title":"Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"31","author":"Brogden","year":"1986","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"issue":"8","key":"10.1016\/j.mimet.2023.106876_bb0090","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/nnm.10.107","article-title":"Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances","volume":"5","author":"Buse","year":"2010","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1021\/mp900138a","article-title":"Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin","volume":"7","author":"Cartiera","year":"2009","journal-title":"Mol. Pharm."},{"issue":"14","key":"10.1016\/j.mimet.2023.106876_bb0100","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.biomaterials.2009.01.057","article-title":"The uptake and intracellular fate of PLGA nanoparticles in epithelial cells","volume":"30","author":"Cartiera","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.mimet.2023.106876_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cbi.2014.11.016","article-title":"Toxicity of cobalt oxide nanoparticles to normal cells; an in vitro and in vivo study","volume":"226","author":"Chattopadhyay","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.colsurfb.2011.02.033","article-title":"Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles","volume":"85","author":"Cheow","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1\u20133","key":"10.1016\/j.mimet.2023.106876_bb0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfa.2011.08.035","article-title":"The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics","volume":"389","author":"Cheow","year":"2011","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"issue":"24","key":"10.1016\/j.mimet.2023.106876_bb0120","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3390\/ma12244093","article-title":"Novel therapeutic strategies applied to Pseudomonas aeruginosa infections in cystic fibrosis","volume":"12","author":"Chirgwin","year":"2019","journal-title":"Materials"},{"key":"10.1016\/j.mimet.2023.106876_bb0125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of DF508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mimet.2023.106876_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in Cystic Fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of liposomal ciprofloxacin to treat lung infections","volume":"8","author":"Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.mimet.2023.106876_bb0140","first-page":"L917","article-title":"CFTR and lung homeostasis","volume":"307","author":"Collawn","year":"2014","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0145","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1021\/acsami.1c14975","article-title":"Hybrid lipid\/polymer nanoparticles to tackle the Cystic Fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference?","volume":"14","author":"Conte","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2006.01.016","article-title":"Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung","volume":"215","author":"Dailey","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.mimet.2023.106876_bb0155","series-title":"Nanoparticle-mediated oxidative stress monitoring and role of nanoparticle for treatment of inflammatory diseases. In nanotechnology in modern animal biotechnology, concepts and applications","first-page":"97","author":"Dalal","year":"2019"},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0160","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/archdischild-2013-304400","article-title":"Recent advances in the management of cystic fibrosis","volume":"99","author":"Davies","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.mimet.2023.106876_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0170","article-title":"Newly discovered cutting-edge triple combination Cystic Fibrosis therapy: a systematic review","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.mimet.2023.106876_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"issue":"5670","key":"10.1016\/j.mimet.2023.106876_bb0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1093941","article-title":"Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects","volume":"304","author":"Egan","year":"2004","journal-title":"Science"},{"issue":"10059","key":"10.1016\/j.mimet.2023.106876_bb0185","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0190","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/pharmaceutics12020142","article-title":"Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations","volume":"12","author":"Eleraky","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0195","article-title":"Effect of curcumin on experimental models of Cystic Fibrosis: a systematic review","volume":"32","author":"Faramarzi","year":"2022","journal-title":"Innov. J. Pediatr."},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0200","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/genes11040401","article-title":"The impact of the CFTR gene discovery on cystic fibrosis diagnosis, counseling, and preventive therapy","volume":"11","author":"Farrell","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.mimet.2023.106876_bb0205","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2014.03.055","article-title":"Lipid and polymer nanoparticles for drug delivery to bacterial biofilms","volume":"190","author":"Forier","year":"2014","journal-title":"JCR"},{"key":"10.1016\/j.mimet.2023.106876_bb0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1166\/jnn.2014.9015","article-title":"Mucus as barrier for drug delivery by nanoparticles","volume":"14","author":"Fr\u00f6hlich","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.mimet.2023.106876_bb0215","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/biomedicines10092137","article-title":"Lipid based drug delivery systems for diseases managements","volume":"10","author":"Gbian","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/IIO.0000000000000360","article-title":"Delivery of genetic information: viral vector and nonviral vector gene therapies","volume":"61","author":"Gemayel","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.mimet.2023.106876_bb0225","doi-asserted-by":"crossref","first-page":"32227","DOI":"10.1074\/jbc.M110.155259","article-title":"The cystic fibrosis trans-membrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel","volume":"285","author":"Gentzsch","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0230","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/ijms21072536","article-title":"Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy","volume":"21","author":"Gessner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0235","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges","volume":"45","author":"Gomes-da-Silva","year":"2012","journal-title":"Acc. Chem. Res."},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.mimet.2023.106876_bb0245","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.20120562","article-title":"Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype","volume":"209","author":"Gustafsson","year":"2012","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.mimet.2023.106876_bb0250","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1128\/AAC.03170-14","article-title":"Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms","volume":"58","author":"Habash","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2023.106876_bb0255","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00005-011-0113-6","article-title":"The cystic fibrosis neutrophil: a specialized yet potentially defective cell","volume":"59","author":"Hayes","year":"2011","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-1993(02)00104-2","article-title":"Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies","volume":"1","author":"H\u00f8iby","year":"2002","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1286-4579(00)01349-6","article-title":"Pseudomonas aeruginosa and the in vitroand in vivo biofilm mode of growth","volume":"3","author":"H\u00f8iby","year":"2001","journal-title":"Microbes Infect."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0275","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2013.01.029","article-title":"Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs","volume":"167","author":"Howell","year":"2013","journal-title":"JCR"},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0280","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s13346-013-0132-4","article-title":"Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases","volume":"3","author":"Howell","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.mimet.2023.106876_bb0285","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mimet.2023.106876_bb0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0295","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009498","article-title":"The CFTR ion channel: gating, regulation, and anion permeation","volume":"3","author":"Hwang","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.mimet.2023.106876_bb0300","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1099\/jmm.0.047100-0","article-title":"Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved","volume":"61","author":"Hwang","year":"2012","journal-title":"J. Med. Microbiol."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0305","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1128\/AAC.42.7.1641","article-title":"In-vitro and in- vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa","volume":"42","author":"Ishida","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mimet.2023.106876_bb0310","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.colsurfb.2016.03.040","article-title":"Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. design and characterization","volume":"143","author":"Islan","year":"2016","journal-title":"Colloids Surf. B."},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0315","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1513\/AnnalsATS.201701-058OC","article-title":"An observational study of outcomes and tolerances in patients with Cystic Fibrosis initiated on Lumacaftor\/Ivacaftor","volume":"14","author":"Jennings","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"10","key":"10.1016\/j.mimet.2023.106876_bb0320","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI5731","article-title":"\u0394F508 CFTR protein expression in tissues from patients with cystic fibrosis","volume":"103","author":"K\u00e4lin","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mimet.2023.106876_bb0325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fphar.2020.00487","article-title":"Nanocurcumin: a promising candidate for therapeutic applications","volume":"11","author":"Karthikeyan","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0330","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13063-021-05224-6","article-title":"The effects of nano-curcumin as a nutritional strategy on clinical and inflammatory factors in children with cystic fibrosis: a protocol study and review article","volume":"22","author":"Kianifar","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0340","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2018.08.014","article-title":"Antimicrobial resistance in cystic fibrosis international working group defining antimicrobial resistance in cystic fibrosis","volume":"17","author":"Kidd","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0345","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial","volume":"6","author":"Konstan","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.mimet.2023.106876_bb0350","series-title":"Poster at the 8th European Conference on Rare Diseases & Orphan Products (ECRD): Poster 108, Edinburgh","article-title":"Evidence for reduced rate of lung function decline and sustained benefit with combination lumacaftor and ivacaftor (LUM\/IVA) therapy in patients (pts) \u2265 12 years of age with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation","author":"Konstan","year":"2016"},{"issue":"Suppl. 1","key":"10.1016\/j.mimet.2023.106876_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/08958370902942517","article-title":"Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs","volume":"21","author":"Kreyling","year":"2009","journal-title":"Inhal. Toxicol."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/nn403256v","article-title":"Aireblood barrier translocation of tracheally instilled gold nanoparticles inversely depends on particle size","volume":"8","author":"Kreyling","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.mimet.2023.106876_bb0365","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2020.10.010","article-title":"Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles","volume":"157","author":"Lababidi","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0370","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1096\/fj.13-227330","article-title":"The silent codon change I507-ATC->ATT contributes to the severity of the \u0394F508 CFTR channel dysfunction","volume":"27","author":"Lazrak","year":"2013","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0375","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1378\/chest.06-1524","article-title":"Levofloxacin pharmacokinetics in adult cystic fibrosis","volume":"131","author":"Lee","year":"2007","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0380","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0385","first-page":"548","article-title":"Review of rapid advances in cystic fibrosis","volume":"117","author":"Link","year":"2020","journal-title":"Mo. Med."},{"key":"10.1016\/j.mimet.2023.106876_bb0390","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mimet.2023.106876_bb0395","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13205-019-1577-z","article-title":"Gold nanoparticle surface engineering strategies and their applications in biomedicine and diagnostics","volume":"9","author":"Mahato","year":"2019","journal-title":"3 Biotech"},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0405","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/sj.bjp.0706185","article-title":"Curcumin modulation of Na, K-ATPase: phosphoenzyme accumulation, decreased K+ occlusion, and inhibition of hydrolytic activity","volume":"145","author":"Mahmmoud","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0410","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1517\/14656566.2013.790366","article-title":"Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials","volume":"14","author":"M\u00e1iz","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.mimet.2023.106876_bb0415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int. J. Nanomedicine"},{"issue":"28","key":"10.1016\/j.mimet.2023.106876_bb0420","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.1073\/pnas.1502281112","article-title":"Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy","volume":"112","author":"Mastorakos","year":"2015","journal-title":"PNAS"},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0425","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.mimet.2023.106876_bb0430","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1038\/ncomms7952","article-title":"Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs","volume":"6","author":"McNeer","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mimet.2023.106876_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biomaterials.2018.04.056","article-title":"Walking the line: the fate of nanomaterials at biological barriers","volume":"174","author":"Meng","year":"2018","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0440","first-page":"59","article-title":"CFTR modulator therapy for rare CFTR mutants","volume":"2","author":"Mergiotti","year":"2022","journal-title":"J. Dent. Res."},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0445","doi-asserted-by":"crossref","first-page":"79220","DOI":"10.1371\/journal.pone.0079220","article-title":"Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mimet.2023.106876_bb0450","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.mimet.2023.106876_bb0455","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0460","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00018-016-2390-z","article-title":"The gating of the CFTR channel","volume":"74","author":"Moran","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"1\u20132","key":"10.1016\/j.mimet.2023.106876_bb0465","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2015.12.028","article-title":"Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis","volume":"498","author":"Moreno-Sastre","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0470","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/02652048.2016.1242665","article-title":"Stability study of sodium colistimethate-loaded lipid nanoparticles","volume":"33","author":"Moreno-Sastre","year":"2016","journal-title":"J. Microencapsul."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.mimet.2023.106876_bb0475","doi-asserted-by":"crossref","first-page":"S598","DOI":"10.1093\/clinids\/13.Supplement_7.S598","article-title":"Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and\/or cephalosporin antibiotics","volume":"13","author":"Moss","year":"1991","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.mimet.2023.106876_bb0485","doi-asserted-by":"crossref","first-page":"18877","DOI":"10.1038\/srep18877","article-title":"Potent antibacterial nanoparticles against biofilm and intracellular bacteria","volume":"6","author":"Mu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mimet.2023.106876_bb0490","article-title":"Improving ciprofloxacin antimicrobial activity through lipid nanoencapsulation or non-thermal plasma on Pseudomonas aeruginosa biofilms","volume":"64","author":"Muraca","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.mimet.2023.106876_bb0495","first-page":"2217","article-title":"Gold-functionalized magnetic nanoparticles restrict growth of Pseudomonas aeruginosa","volume":"9","author":"Niemirowicz","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"5","key":"10.1016\/j.mimet.2023.106876_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0505","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/toxsci\/kfh287","article-title":"The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass","volume":"82","author":"Nygaard","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.mimet.2023.106876_bb0510","series-title":"Controlled Pulmonary Drug Delivery","first-page":"21","article-title":"Pulmonary drug metabolism, clearance, and absorption","author":"Olsson","year":"2011"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0515","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12931-015-0223-5","article-title":"Nanotechnology in respiratory medicine","volume":"16","author":"Omlor","year":"2015","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0520","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1128\/AAC.00306-13","article-title":"Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model","volume":"57","author":"Ong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0525","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/2472630318824334","article-title":"Nanomedicine for cystic fibrosis","volume":"24","author":"Ong","year":"2019","journal-title":"SLAS Technol."},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0530","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1172\/JCI129635","article-title":"Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation","volume":"130","author":"Ortiz-Mu\u00f1oz","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.mimet.2023.106876_bb0535","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.3390\/ijms15045852","article-title":"Nanoparticle-mediated pulmonary drug delivery: a review","volume":"15","author":"Paranjpe","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mimet.2023.106876_bb0540","series-title":"Synth. Messenger RNA Cell Metab. Modul","first-page":"29","article-title":"In vitro transcription of long RNA containing modified nucleosides","author":"Pardi","year":"2013"},{"key":"10.1016\/j.mimet.2023.106876_bb0545","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"JCR"},{"issue":"1\u20132","key":"10.1016\/j.mimet.2023.106876_bb0550","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijpharm.2014.10.048","article-title":"Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis","volume":"477","author":"Pastor","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2023.106876_bb0555","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2019.03.051","article-title":"Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis","volume":"563","author":"Patel","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0560","first-page":"500","article-title":"CFTR modulators for the treatment of cystic fibrosis","volume":"39","author":"Pettit","year":"2014","journal-title":"PT"},{"issue":"40","key":"10.1016\/j.mimet.2023.106876_bb0565","doi-asserted-by":"crossref","first-page":"eabo0522","DOI":"10.1126\/sciadv.abo0522","article-title":"In vivo correction of cystic fibrosis mediated by PNA nanoparticles","volume":"8","author":"Piotrowski-Daspit","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0570","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","article-title":"Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic","volume":"26","author":"Puri","year":"2009","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"7","key":"10.1016\/j.mimet.2023.106876_bb0575","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00249-017-1238-2","article-title":"Efflux drug transporters at the forefront of antimicrobial resistance","volume":"46","author":"Rahman","year":"2017","journal-title":"Eur. Biophys. J."},{"issue":"5","key":"10.1016\/j.mimet.2023.106876_bb0580","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.mimet.2023.106876_bb0585","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/S1516-89132013005000011","article-title":"Nanoparticle-based drug delivery systems: promising approaches against infections","volume":"57","author":"Ranghar","year":"2014","journal-title":"Braz. Arch. Biol. Technol."},{"key":"10.1016\/j.mimet.2023.106876_bb0595","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic Fibrosis Foundation Pulmonary Guidelines: use of CFTR modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0600","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.3390\/cells10113260","article-title":"Impact of airway inflammation on the efficacy of CFTR modulators","volume":"10","author":"Ribeiro","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.mimet.2023.106876_bb0605","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mimet.2023.106876_bb0610","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0615","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2009.07.001","article-title":"Nanodelivery in airway diseases: challenges and therapeutic applications","volume":"6","author":"Roy","year":"2010","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.mimet.2023.106876_bb0620","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jcf.2015.12.005","article-title":"Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients","volume":"15","author":"Sans-Serramitjana","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.mimet.2023.106876_bb0625","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/1061186X.2013.829078","article-title":"Nanotechnology approaches for inhalation treatment of fibrosis","volume":"21","author":"Savla","year":"2013","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0630","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/ntrev-2019-0017","article-title":"Toxicity of metallic nanoparticles in the central nervous system","volume":"8","author":"Sawicki","year":"2019","journal-title":"Nanotechnol. Rev."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0635","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1039\/D1MA00069A","article-title":"Nano-enabled theranostics for cancer","volume":"2","author":"Sharmiladevi","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mimet.2023.106876_bb0640","series-title":"Polymyxin","author":"Shatri","year":"2023"},{"issue":"S40","key":"10.1016\/j.mimet.2023.106876_bb0645","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ppul.23240","article-title":"Breakthrough therapies: cystic fibrosis potentiators and correctors","volume":"50","author":"Solomon","year":"2015","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.mimet.2023.106876_bb0650","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/mt.2011.160","article-title":"N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles","volume":"19","author":"Suk","year":"2011","journal-title":"Mol. Ther."},{"issue":"41","key":"10.1016\/j.mimet.2023.106876_bb0655","doi-asserted-by":"crossref","first-page":"12197","DOI":"10.1002\/ange.201506030","article-title":"Self-assembled DNA nanoclews for the efficient delivery of CRISPR\u2013Cas9 for genome editing","volume":"127","author":"Sun","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"issue":"23","key":"10.1016\/j.mimet.2023.106876_bb0660","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.3390\/molecules26237109","article-title":"The multifaceted role of curcumin in advanced nanocurcumin form in the treatment and management of chronic disorders","volume":"26","author":"Tagde","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0665","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13063-021-05224-6","article-title":"The effects of nano-curcumin as a nutritional strategy on clinical and inflammatory factors in children with cystic fibrosis: the study protocol for a randomized controlled trial","volume":"22","author":"Talebi","year":"2021","journal-title":"Trials."},{"issue":"46","key":"10.1016\/j.mimet.2023.106876_bb0670","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1073\/pnas.0905998106","article-title":"Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier","volume":"106","author":"Tang","year":"2009","journal-title":"PNAS"},{"issue":"24","key":"10.1016\/j.mimet.2023.106876_bb0675","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202100531","article-title":"Tobramycin liquid crystal nanoparticles eradicate cystic fibrosis-related Pseudomonas aeruginosa biofilms","volume":"17","author":"Thorn","year":"2021","journal-title":"Small"},{"issue":"1\u20132","key":"10.1016\/j.mimet.2023.106876_bb0680","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.05.013","article-title":"Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis","volume":"527","author":"Torge","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.mimet.2023.106876_bb0685","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2016.10.025","article-title":"Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach","volume":"515","author":"T\u00fcreli","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mimet.2023.106876_bb0690","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"T\u00fcreli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0695","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano-and micro-carriers for pulmonary delivery: challenges and promises","volume":"64","author":"Ungaro","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0705","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12989-014-0036-6","article-title":"Ultrafine carbon particle mediated cardiovascular impairment of aged spontaneously hypertensive rats","volume":"11","author":"Upadhyay","year":"2014","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.mimet.2023.106876_bb0715","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/TCRM.S75208","article-title":"Long-term safety and efficacy of tobramycin in the management of cystic fibrosis","volume":"11","author":"V\u00e1zquez-Espinosa","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"issue":"246","key":"10.1016\/j.mimet.2023.106876_bb0720","doi-asserted-by":"crossref","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish DF508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mimet.2023.106876_bb0725","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","article-title":"Nanomedicine approaches for the pulmonary treatment of cystic fibrosis","volume":"7","author":"Velino","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"30","key":"10.1016\/j.mimet.2023.106876_bb0730","doi-asserted-by":"crossref","first-page":"17823","DOI":"10.1074\/jbc.270.30.17823","article-title":"In vitro fusion of reticulocyte endocytic vesicles with liposomes","volume":"270","author":"Vidal","year":"1995","journal-title":"JBC"},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0735","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-3155-8-22","article-title":"Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis","volume":"8","author":"Vij","year":"2010","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mimet.2023.106876_bb0740","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.2147\/IJN.S104166","article-title":"Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii","volume":"11","author":"Wan","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.mimet.2023.106876_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114309","article-title":"Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches","volume":"185","author":"Wang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0750","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/imr.12266","article-title":"Macrophage defense mechanisms against intracellular bacteria","volume":"264","author":"Weiss","year":"2015","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.mimet.2023.106876_bb0755","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2013.05.035","article-title":"Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus","volume":"170","author":"Xu","year":"2013","journal-title":"JCR"},{"key":"10.1016\/j.mimet.2023.106876_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113891","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment","volume":"176","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.mimet.2023.106876_bb0765","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.mimet.2023.106876_bb0770","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/jcm5090082","article-title":"Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery","volume":"5","author":"Yhee","year":"2016","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.mimet.2023.106876_bb0775","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"30","key":"10.1016\/j.mimet.2023.106876_bb0780","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1021\/acsami.7b08163","article-title":"Biodegradable amino-ester nanomaterials for Cas9 mRNA delivery in vitro and in vivo","volume":"9","author":"Zhang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["Journal of Microbiological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167701223002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167701223002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:38:21Z","timestamp":1736336301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167701223002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":154,"alternative-id":["S0167701223002105"],"URL":"https:\/\/doi.org\/10.1016\/j.mimet.2023.106876","relation":{},"ISSN":["0167-7012"],"issn-type":[{"value":"0167-7012","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticle-based platforms for targeted drug delivery to the pulmonary system as therapeutics to curb cystic fibrosis: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mimet.2023.106876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106876"}}